Our work provides an alternate therapeutic option for granulocyte recovery in SCN patients by using lower doses of G-CSF in combination with approaches to downregulate or degrade SERF1, thereby decreasing the risk of these patients to develop secondary MDS and AML. Here, SERF1A is linked to myelodysplastic syndrome.